EMERYVILLE, Calif., March 10 Bionovo, Inc.(Nasdaq: BNVI) announced today results from two independent physician surveyswhich showed MF101 could become first-line treatment for menopausal vasomotorsymptoms (hot flashes). In both qualitative and quantitative studies, 124physicians board certified in internal medicine or obstetrics and gynecologyspecializing in the treatment of menopause reported MF101, if approved, wouldbe their drug of choice for the treatment of hot flashes. In addition, 92% ofphysicians reported they would prescribe MF101 before prescribing anantidepressant agent for hot flashes.
"These results confirm what we have believed for over a decade. Bothphysicians and women are eagerly awaiting a safe and new alternative drug forthe treatment of menopausal symptoms," said Mary Tagliaferri, M.D., Bionovo'sPresident and CMO. "The multiple medical risks associated with estrogentherapies make these drugs undesirable, and the antidepressant agentscurrently used off label for this indication are poorly tolerated due to theirmany side effects. In contrast, our lead drug candidate, MF101, showed in aPhase 2 study that it is effective at alleviating hot flashes and is extremelywell tolerated due to a very favorable safety profile."
In addition to placing MF101 at the top of the list of treatment optionsfor menopausal symptoms, physicians also reported the following:
"These independent physician studies provide us with further evidence thatif available, MF101 can be a blockbuster drug once it hits the market," saidIsaac Cohen, O.M.D., Chairman and CEO of Bionovo. "A safe and effective drugshould be able to earn a large share of the $6-7 Billion of demand thatexisted in the past for this indication."
Complete results from the independent physician surveys are being preparedfor publication.
Bionovo is a pharmaceutical company focused on the discovery anddevelopment of safe and effective treatments for women's health and cancer,markets with significant unmet needs and billions in potential annual revenue.The company applies its expertise in the biology of menopause and cancer todesign new drugs derived from botanical sources which have novel mechanisms ofaction. Based on the results of early and mid-stage clinical trials, Bionovobelieves they have discovered new classes of drug candidates within their richpipeline with the potential to be leaders in their markets. Bionovo isheadquartered in Emeryville, California and is traded on the NASDAQ CapitalMarket under the symbol, "BNVI". For more information about Bionovo and itsprograms, visit: http://www.bionovo.com.
Forward Looking Statements
This release contains certain forward-looking statements relating to thebusiness of Bionovo, Inc. that can be identified by the use of forward-lookingterminology such as "believes," "expects," or similar expressions. Suchforward-looking statements involve known and unknown risks and uncertainties,including uncertainties relating to product development, efficacy and safety,regulatory actions or delays, the ability to obtain or maintain patent orother proprietary intellectual property protection, market acceptance,physician acceptance, third party reimbursement, future capital requirements,competition in general and other factors that may cause actual results to bematerially different from those described herein as anticipated, believed,estimated or expected. Certain of these risks and uncertainties are or will bedescribed in greater detail in our filings with the Securities and ExchangeCommission, which are available at http://www.sec.gov. Bionovo, Inc. is underno obligation (and expressly disclaims any such obligation) to update or alterits forward-looking statements whether as a result of new information, futureevents or otherwise.-- The accepted threshold for efficacy of a drug for vasomotor symptoms is